

Bologna, 14 04 2020

Third update regarding the possible use of CytoSorb as adjuvant therapy in arising complications in patients with Covid-19/Coronavirus (Sars-CoV-2) infections.

Given the clinical rationale and the results obtained in the past months, the US FDA has approved the use of CytoSorb as therapy for Covid-19 patient.

The FDA approval letter sent to CytoSorbents states:

"Based on bench performance testing and reported clinical experience, FDA has concluded that the CytoSorb device may be effective at treating certain patients with confirmed COVID-19 by removing various pro-inflammatory cytokines from their blood. FDA believes, based on the totality of scientific evidence available, that the removal of pro-inflammatory cytokines may ameliorate cytokine storm due to the overabundance of pro-inflammatory cytokines and, in turn, provide clinical benefit.....there is no adequate, approved, and available alternative to the emergency use of the CytoSorb device for the treatment of these COVID-19 patients...."

Moreover, we underline the treatment posology given in the FDA approved instructions for use for Covid-19 patients:

- **Day 1: Change device every 12 hours;**
- **Day 2: Change device at 24 hours;**
- **Day 3: Change device at 24 hours;**
- **Clinical assessment to be made after 72 hours of use to determine if patient is receiving clinical benefit for continuation of therapy**

With this approval, the results, albeit preliminary, that have emerged in recent months in hospitals where treatment with CytoSorb has been introduced, including Italy, are considered.

We know that there is still much to study and discuss to understand how to use appropriately this therapeutic opportunity in critically ill patients with Covid-19.

Therefore, we invite you to attend the Webinar "**Cytokine adsorption in severely ill covid-19 patients – actual scientific results and clinical experiences**" (Chais: J. Kellum, L. Gattinoni) on

Thursday 16th April '20

13,00-14,30

Register here: https://zoom.us/webinar/register/WN_EV6rtOwAQGS2s0mBYZ27Rg

Webinar

CytoSorbents invites you to join the upcoming webinar on:

Cytokine adsorption in severely ill COVID-19 patients – rationale and clinical experience

Chairs: Prof. John Kellum, Pittsburgh, USA and Prof. Luciano Gattinoni, Göttingen, Germany

Speakers: Prof. Zhiyong Peng, Wuhan, China; Dr. Ivano Riva, Bergamo, Italy; Prof. Giorgio Berlot, Triest, Italy; Dr. Alexander Supady, Freiburg, Germany; Prof. Peter Hegyi, Pecs, Hungary

Agenda

- Introduction – why hemoadsorption seems to be a useful treatment option
John Kellum
- Safety and feasibility of CytoSorb therapy in COVID-19 patients – the Wuhan experience
Zhiyong Peng
- It is more than just cytokine removal – the Bergamo and Triest experience
Ivano Riva and Giorgio Berlot
- Combination of ECMO and CytoSorb in COVID-19 patients – when and how should we do it
Alexander Supady
- We have to collect data to create evidence! CYTOAID – an international multicenter observational trial
Peter Hegyi
- Summary
Luciano Gattinoni

We look forward to welcoming you to our webinar! Your CytoSorbents Europe team

Date and Time

Thursday, April 16th | 1:00pm - 2:30pm CEST

Please follow the link to register to the ZOOM webinar.
An email with the JOIN link will be sent from ZOOM 1h prior
to the meeting.

cyto.news/covid19webinar

